Determinants of tamoxifen sensitivity control the nature of the aynergistic interaction between tamoxifen and cisplatin

Cancer Research

Volumn 56, Issue 17, 1996, Pages 3993-3997

  McClay, Edward F ^a,c   Jones, Jeffrey A ^a   Winski, Paul J ^a   Albright, Kathleen D ^b   Christen, Randolph D ^b,d,e   Howell, Stephen B ^b,e  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^e Clayton Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; TAMOXIFEN;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; TUMOR CELL CULTURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CISPLATIN; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; MELANOMA; PHENOTYPE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0029846377     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. McClay, E. F , Mastrangelo, M J , Bellet, R. E., and Berd, D Combination chemo/hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep., 71: 465-469, 1987
2. McClay, E F., Mastrangelo, M J., Berd, D , and Bellet, R E Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int. J. Cancer, 50 553-556, 1992.
3. McClay, E. F., Mastrangelo, M J , Sprandio, J. D., Bellet, R E., and Berd, D The importance of tamoxifen to a cisplatin containing regimen in the treatment of metastatic melanoma Cancer (Phila.), 63: 1292-1295, 1989.
4. McClay, E F., McClay, M. E., Albright, K A., Jones, J. A., Christen, R., Alcaraz, J , and Howell, S B. Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma: a biologically important observation. Cancer (Phila ), 72. 1914-1918, 1993.
5. McClay, E. F , Mastrangelo, M. J , Berd, D., and Bellet, R E. Effective combination chemo/hormal therapy for malignant melanoma experience with three consecutive trials Int J. Cancer, 50: 553-556, 1992
6. Chou, T. C , and Talalay, P Quantitative analysis of dose-effect relationships the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul., 22, 27-55, 1986
7. Berebaum, M. C. What is synergy? Pharmacol Rev., 41: 93-142, 1989.
8. McClay, E F., Christen, R., Albright, K A., Jones, J. A., Eastman, A., and Howell, S B Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res. 52, 6790-6796, 1992.
9. McClay, E. F., Albright, K. A., Jones, J A., Christen, R., and Howell, S. B Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells Cancer Res , 53: 1571-1576, 1993.
10. Taetle, R , Jones, O., Honeysett, J., Abramson, I., Bradshaw, C., and Reid, S. Characterization of xenograft-derived melanoma cell lines Cancer (Phila.), 60: 1836-1841, 1987.
11. McClay, E. F., Albright, K. D., Jones, J. A , Eastman, A., Christen, R , and Howell, S. B. Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res., 52: 6790-6796, 1992.
12. Andrews, P. A., and Howell, S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2: 35-43, 1990.
13. Han, X , and Liehr, J. G Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res , 52 1360-1363, 1992.
14. Pongracz, K., Pathak, D. N., Nakamura, T, Burlingame, A. L , and Bodell, W. J. Activation of the tamoxifen derivatve metabolite E to form DNA adducts comparison with the adducts formed by microsomal activation of tamoxifen. Cancer Res., 55, 3012-3015, 1995.
15. Chen, A Y., Yu, C., Gatto, B., and Liu, L. F. DNA minor groove-binding ligands a different class of mammalian DNA topoisomerases I inhibitors. Proc. Natl. Acad Sci. USA, 90: 8131-8135, 1993
16. Lemmontt, J. F , Azzaria, M., and Gros, P Increased mdr gene expression and decreased drug accumulation in multi-drug resistant human melanoma cells. Cancer Res., 48: 6348-6353, 1988.
17. Ramu, A , Glauberger, D , and Faks, Z Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other treparanol analogues. Cancer Res., 44 4392-4395, 1984
18. Chatterjee, M., and Harris, A. L. Reversal of acquired resistance to adriamycin in CHO cells by tamoxifen and 4-hydroxytamoxifen role of drug interaction with α1 acid glycoprotein Br. J. Cancer, 62: 712-717, 1990.
19. Fine, R. L , Williams, A , Jett, M , Robertson, C., Jordan, V C., and Trump, D. Tamoxifen (TAM) potentiates the antitumor effect of vinblastine against intrinsically multidrug resistant (mdr) human renal carcinoma cell (RCC) lines. Proc. Am. Assoc. Cancer Res , 31 359, 1990.
20. Noonan, K. E , Beck, C , Holzmayer, T. A , Chin, J. E., Wunder, J. S., Andrulis, I L , Gazdar, A F., Williams, C. L., Griffith, B., Von Hoff, D. D., and Roninson, I. B Quantitative analysis of MDRI (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc. Natl. Acad. Sci. USA, 87 7160-7164, 1990.
21. Christen, R , McClay, E F , Kim, S , Kirmani, S., Plaxe, S., Braly, P , Heath, D. D , Schlinsky, D. R., Wang, J , Yen, S C. C., and Howell, S B. In vivo modulation of doxorubicin by high-dose progesterone. A phase I pharmacokinetic study J. Clin. Oncol., 11: 2417-2426, 1993.
22. Perry, R. R., Kang, Y , and Greaves, B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells Ann. Surg. Oncol., 2: 238-245, 1995.
23. Welsh, J. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens Biochem Cell Biol., 72: 537-545, 1994.
24. McClay, E. F, Albright, K A., Jones, J. A., Christen, R., and Howell, S. B. Tamoxifen modulation of cisplatin cytotxicity in human cancers. Int. J. Cancer, 55: 1018-1022, 1993.